BioNTech lowers sales forecast for COVID-19 vaccine

BERLIN, Nov. 6 (Xinhua) -- German vaccine maker BioNTech on Monday lowered its 2023 sales forecast for its COVID-19 vaccine to around 4 billion euros (4.28 billion U.S. dollars). In spring, the company had still predicted sales of 5 billion euros.

"As a result of later-than-anticipated regulatory approvals and their effect on national vaccination campaign timelines, expected sales have shifted to future periods," BioNTech said in a statement. In addition, charges of more than 1 billion euros on the part of U.S. partner Pfizer would impact sales.